E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Parkinson's disease |
Enfermedad de Parkinson |
|
E.1.1.1 | Medical condition in easily understood language |
Parkinson's disease |
Enfermedad de Parkinson |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• Safety: Evaluate the safety of donepezil administered for 12 months by measuring blood pressure (BP), heart rate (HR), blood tests, Movement Disorders Society Unified Parkinson's Disease Rating Scale part III (MDS UPDRS-III), ECG, and recording of adverse effects. • Primary efficacy: To assess the effects of donepezil administered for 12 months on global cognitive performance by analyzing changes in the Parkinson's Disease-Cognitive Rating Scale (PD-CRS) from baseline to 12 months. |
• Seguridad: Evaluar la seguridad de donepezilo administrado durante 12 meses mediante la realización de medidas de tensión arterial (TA), frecuencia cardiaca (FC), analítica sanguínea, Movement Disorders Society Unified Parkinson's Disease Rating Scale part III (MDS UPDRS-III), ECG, y registro de efectos adversos. • Primario de eficacia: Evaluar los efectos de donepezilo administrado durante 12 meses en el rendimiento cognitivo global analizando cambios en la escala Parkinson's Disease-Cognitive Rating Scale (PD-CRS) desde situación basal a los 12 meses. |
|
E.2.2 | Secondary objectives of the trial |
- To assess the effects on cognitive functional performance by analyzing changes in the Parkinson's Disease-Cognitive Functional Rating Scale (PD-CFRS) - Evaluate the effects in different tests and cognitive domains analyzing the changes in Trail Making Test A (TMT-A), Direct Digit Span (DSd), Trail Making Test B (TMT-B), Phonetic Fluency (FF), Boston Naming Test (BNTr), Semantic fluency (FS), Free and cued selective reminding test (FCSRT), Rey-Osterrieth complex figure test (ROCF), ROCF recall (rROCF), and Judgment of line orientation (JLO) - Evaluate the effects on anxiety, depression, apathy, psychosis, sleep and dysautonomia - Assess the effects on quality of life - Evaluate the effects on the severity and changes in the general clinical state of the patient, - To assess the effects on the subjective cognitive state by analyzing changes in the Patient Global Impression of Change (PGIC) scale. |
- Evaluar los efectos en el rendimiento funcional cognitivo analizando cambios en la escala Parkinson's Disease-Cognitive Functional Rating Scale (PD-CFRS) - Evaluar los efectos en diferentes pruebas y dominios cognitivos analizando los cambios en Trail Making Test A (TMT-A), Digit Span directo (DSd), Trail Making Test B (TMT-B), Fluencia Fonética (FF), Boston Naming Test reducida (BNTr), Fluencia semántica (FS), Free and cued selective reminding test (FCSRT), Rey-Osterrieth complex figure test (ROCF), recuerdo de ROCF (rROCF), y Judgment of line orientation (JLO) - Evaluar los efectos en ansiedad, depresión, apatía, psicosis, sueño y disautonomía - Evaluar los efectos en la calidad de vida - Evaluar los efectos en la severidad y los cambios del estado clínico general del paciente , - Evaluar los efectos en el estado cognitivo subjetivo analizando cambios en la escala Patient Global Impression of Change (PGIC) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- 50-80 years (included) - Diagnosis of PD based on MDS criteria(45) - Neuroimaging compatible with PD - Hoehn and Yahr Stadium (H&Y) I-III (included) - Persistent subjective cognitive complaints in the 6 months prior to Screening - Diagnosis of MCI-EP by MDS MCI-EP criteria: - Duration of DCL-EP of at least 3 months prior to Screening - Stable dopaminergic treatment in the 4 weeks prior to Screening |
- 50-80 años (incluidos) - Diagnóstico de EP en base a criterios MDS(45) - Neuroimagen compatible con EP - Estadio Hoehn y Yahr (H&Y) I-III (incluidos) - Quejas cognitivas subjetivas persistentes en los 6 meses previos al Screening - Diagnóstico de DCL-EP por criterios MDS DCL-EP: - Duración de DCL-EP de, al menos, 3 meses previo al Screening - Tratamiento dopaminérgico estable en las 4 semanas previas al Screening |
|
E.4 | Principal exclusion criteria |
- Criteria for dementia associated with PD(49) - Severe motor complications (moderate-severe motor fluctuations defined as a score >1 on MDS UPDRS Part IV item 42; or disabling dyskinesias defined as a score >1 on MDS UPDRS Part IV item 36) - History of Deep Brain Stimulation - Active or antipsychotic psychosis, major hallucinations, HADS score ≥11, active impulse control disorder, or other active severe behavioral disorders - Active treatment with anticholinergics, acetylcholinesterase inhibitors or other systemic cholinergic enhancers, or neuroleptics - Hypersensitivity or intolerance to donepezil, to piperidine derivatives, to lactose or to any of the excipients of the active drug |
- Criterios de demencia asociada a EP(49) - Complicaciones motoras severas (fluctuaciones motoras moderadas-severas definidas como una puntuación >1 del ítem 42 de la parte IV de la MDS UPDRS; o discinesias incapacitantes definidas como una puntuación >1 en el ítem 36 de la parte IV de la MDS UPDRS) - Historia de Estimulación Cerebral Profunda - Psicosis activa o con tratamiento antipsicótico, alucinaciones mayores, puntuación HADS ≥11, trastorno del control de impulsos activo u otros trastornos conductuales severos activos - Tratamiento activo con anticolinérgicos, inhibidores de la acetilcolinesterasa u otros potenciadores colinérgicos sistémicos, o neurolépticos - Hipersensibilidad o intolerancia a donepezilo, a derivados de piperidina, a la lactosa o a alguno de los excipientes del fármaco activo |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Parkinson's Disease-Cognitive Rating Scale (PD-CRS): |
Parkinson's Disease-Cognitive Rating Scale (PD-CRS): |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Trail Making Test A (TMT-A) Direct Digit Span (DSd) Trail Making Test B (TMT-B) Boston Nomination Test reduced (BNTr) phonetic fluency semantic fluency Free and Cued Selective Reminding Test (FCSRT) Hospital Anxiety and Depression Scale (HADS) Starkstein Apathy Scale (AS) Neuropsychiatric Inventory (NPI): MDS UPDRS-I and -II Schwab & England Scale (S&E) 8-item Parkinson's Disease Questionnaire (PDQ-8): Clinical Global Impressions (CGI-S and CGI-I) Patients Global Impression of Change (PGIC) Montreal Cognitive Assessment (MoCA) |
Trail Making Test A (TMT-A) Digit Span directo (DSd) Trail Making Test B (TMT-B) Boston Nomination Test reducida (BNTr) Fluencia fonética Fluencia semántica Free and Cued Selective Reminding Test (FCSRT) Hospital Anxiety and Depression Scale (HADS) Starkstein Apathy Scale (AS) Neuropsychiatric Inventory (NPI): MDS UPDRS-I y -II Escala de Schwab & England (S&E) 8-item Parkinson’s Disease Questionnaire (PDQ-8): Clinical Global Impressions (CGI-S y CGI-I) Patients Global Impression of Change (PGIC) Montreal Cognitive Assessment (MoCA) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |